ArticleFood science & nutrition2025
Antioxidant, Hypoglycemic, and Hypolipidemic Effects of Puerarin In Vivo.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Protective effects and mechanisms of puerarin in ovariectomized animal models of osteoporosis: a systematic review and meta-analysis of preclinical studies.Frontiers in physiology · 2026Pooled it
- Danshen (Antioxidants (Basel, Switzerland) · 2026Article
- Puerarin Reverses UV-Induced Epigenetic Silencing of the Wnt/β-Catenin-KIT Axis to Mitigate Skin Fibroblast Aging.International journal of molecular sciences · 2026Article
- Ameliorative effects of aFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Puerarin (PUE) exhibits various pharmacological effects. This study evaluated its antioxidant, hypoglycemic, and hypolipidemic effects in vivo using models of aging, diabetes, and hyperlipidemia. D-galactose-induced aging, streptozotocin (STZ)-induced diabetic, and high-fat diet-induced hyperlipidemic mouse models were established. To evaluate the therapeutic effects, mice were administered various doses of PUE (50, 100, and 200 mg/kg). Results showed that PUE treatment improved antioxidant enzyme activities and reduced serum and liver malondialdehyde (MDA) levels in aging mice, thereby mitigating cellular oxidative stress. In diabetic mice, fasting blood glucose (FBG) levels were observed to decrease, while hepatic hexokinase (HK) activity, pyruvate kinase (PK) activity, and insulin levels increased after 7 weeks of PUE treatment. Furthermore, PUE significantly enhanced blood lipid profiles and antioxidant enzyme properties in diabetic mice. In hyperlipidemic mice, PUE administration led to decreased levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), while increasing high-density lipoprotein cholesterol (HDL-C). These findings indicate that PUE possesses antioxidant, hypoglycemic, and hypolipidemic properties and shows potential for treating aging and related diseases like type 2 diabetes and hyperlipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.